These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 22371753)
21. Natalizumab for induction of remission in Crohn's disease. MacDonald JK; McDonald JW Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580 [TBL] [Abstract][Full Text] [Related]
22. Teriflunomide for multiple sclerosis. He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682 [TBL] [Abstract][Full Text] [Related]
23. Pharmacological treatment for memory disorder in multiple sclerosis. He D; Zhang Y; Dong S; Wang D; Gao X; Zhou H Cochrane Database Syst Rev; 2013 Dec; (12):CD008876. PubMed ID: 24343792 [TBL] [Abstract][Full Text] [Related]
24. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Nikfar S; Rahimi R; Rezaie A; Abdollahi M Dig Dis Sci; 2009 Jun; 54(6):1157-70. PubMed ID: 18770034 [TBL] [Abstract][Full Text] [Related]
25. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972 [TBL] [Abstract][Full Text] [Related]
26. Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Sun Y; Yang Y; Wang Z; Jiang F; Chen Z; Wang Z Front Pharmacol; 2020; 11():589146. PubMed ID: 33658933 [No Abstract] [Full Text] [Related]
27. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481 [TBL] [Abstract][Full Text] [Related]
28. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
29. Cannabis for the treatment of ulcerative colitis. Kafil TS; Nguyen TM; MacDonald JK; Chande N Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638 [TBL] [Abstract][Full Text] [Related]
30. Tocilizumab for giant cell arteritis. Antonio AA; Santos RN; Abariga SA Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013484. PubMed ID: 34420204 [TBL] [Abstract][Full Text] [Related]
31. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. Dalton CM; Miszkiel KA; Barker GJ; MacManus DG; Pepple TI; Panzara M; Yang M; Hulme A; O'Connor P; Miller DH J Neurol; 2004 Apr; 251(4):407-13. PubMed ID: 15083284 [TBL] [Abstract][Full Text] [Related]
33. Tocilizumab for giant cell arteritis. Antonio AA; Santos RN; Abariga SA Cochrane Database Syst Rev; 2022 May; 5(5):CD013484. PubMed ID: 35560150 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Cree BA; Stuart WH; Tornatore CS; Jeffery DR; Pace AL; Cha CH Arch Neurol; 2011 Apr; 68(4):464-8. PubMed ID: 21482925 [TBL] [Abstract][Full Text] [Related]
35. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Khanna R; Preiss JC; MacDonald JK; Timmer A Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580 [TBL] [Abstract][Full Text] [Related]
36. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. Butzkueven H; Licata S; Jeffery D; Arnold DL; Filippi M; Geurts JJ; Santra S; Campbell N; Ho PR; BMJ Open; 2020 Oct; 10(10):e038861. PubMed ID: 33082194 [TBL] [Abstract][Full Text] [Related]
37. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease. Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765 [TBL] [Abstract][Full Text] [Related]
38. Etrolizumab for induction of remission in ulcerative colitis. Rosenfeld G; Parker CE; MacDonald JK; Bressler B Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451 [TBL] [Abstract][Full Text] [Related]
40. [Efficacy and safety of natalizumab for multiple sclerosis and Crohn's disease: a meta analysis]. Li YY; Li YP; Sun X; Wang L; Wen J; Cheng L Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Oct; 32(5):533-42. PubMed ID: 21050557 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]